1LAB SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
1LAB SA - overview
Established
2017
Location
Manno, -, Switzerland
Primary Industry
Biotechnology
About
Based in Manno, Switzerland, and founded in 2017, 1LAB is a provider of healthcare testing services that specializes in preclinical in vitro testing, replicating human arteries, skin, and mucosa utilizing biomaterial scaffolding and tissue engineering technology. In November 2023, 1MED SA, a portfolio company of Apposite Capital, acquired 1LAB. The company's core activities encompass research, consulting, and the design of devices in the biotechnology and medical sectors. 1LAB SA also undertakes the maintenance and repair of biomedical equipment, executes clinical studies, and manages the import and export of medical devices and spare parts.
Current Investors
1MED SA
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Company Stage
Add-on
Total Amount Raised
Subscriber access only
1LAB SA - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | 1LAB SA | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.